Megan Y Tai, OD
Optometry · Santa Clara
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 4
- 1 carrier
- Offices
- 3
Offices
3 locations · Yura Kim OD Inc · Yk Optometry Inc · Peninsula Eye Physicians Medical Group,Inc.
Plans that list them
4 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Tai’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
Original Medicare doctor bills
$14,024
Medicare paid this office $14,024 for 124 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Short return visit (20+ min) | 44 | $4,732 | $83 |
| Established patient complete exam of visual system | 35 | $4,012 | $115 |
| Short return visit | 33 | $3,026 | $49 |
| New patient complete exam of visual system | 12 | $937 | $78 |
Who their Medicare patients are
124 Original Medicare patients in 2024. Average age 79 · Under 65 0% · 85 and older 21% · Women 69% · Also on Medicaid 0% · Health risk score 0.91. At or below the middle of the specialty; the typical optometry clinician is at 0.97.
Conditions among them: High blood pressure 69% · Chronic kidney disease 22% · Atrial fibrillation 18% · Diabetes 15% · Coronary heart disease 15% · Cancer 10% · Heart failure 9% · Depression 9%.
The office billed $37,830, Medicare allowed $20,266 and paid $14,024; for 201 services of 12 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 124 | 201 | 79 | 0.91 | $37,830 | $14,024 |
| 2023 | 129 | 200 | 77 | 0.94 | $34,814 | $12,632 |
| 2022 | 95 | 134 | 76 | 0.88 | $22,677 | $8,090 |
| 2021 | 64 | 75 | 78 | 0.98 | $14,626 | $6,841 |
| 2020 | 31 | 35 | 76 | 0.64 | $8,330 | $3,138 |
| 2019 | 48 | 61 | 77 | 1.04 | $11,783 | $4,401 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 4 services
| Short return visit | 69 | $5,164 | $50 |
| Established patient complete exam of visual system | 34 | $3,406 | $100 |
| New patient complete exam of visual system | 12 | $1,630 | $136 |
| Short return visit (20+ min) | 13 | $1,045 | $75 |
2022: 4 services
| Short return visit | 42 | $2,867 | $49 |
| Established patient complete exam of visual system | 13 | $1,496 | $115 |
| Short return visit (20+ min) | 22 | $1,470 | $67 |
| New patient complete exam of visual system | 12 | $1,208 | $101 |
2021: 3 services
| Short return visit (20+ min) | 31 | $2,743 | $78 |
| New patient complete exam of visual system | 12 | $1,633 | $136 |
| Established patient complete exam of visual system | 11 | $1,306 | $119 |
2020: 1 service
| Established patient problem focused exam of visual system | 13 | $942 | $72 |
2019: 1 service
| Established patient problem focused exam of visual system | 40 | $2,970 | $69 |
Drugs they prescribed that Part D paid
$64,505
Pharmacies billed $64,505 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 536) in 2024. At or below the middle of the specialty; the typical optometry clinician is at 0%.
263 generic and 273 brand-name prescriptions · $64,505 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Restasis | 16 | $21,180 | $1,324 |
| Xiidra | 16 | $17,383 | $1,086 |
| Latanoprost | 224 | $3,718 | $17 |
| Timolol Maleate | 50 | $2,261 | $45 |
| Dorzolamide-Timolol | 12 | $2,195 | $183 |
See all 9 drugs
| Restasis | 16 | $21,180 | $1,324 |
| Xiidra | 16 | $17,383 | $1,086 |
| Latanoprost | 224 | $3,718 | $17 |
| Timolol Maleate | 50 | $2,261 | $45 |
| Dorzolamide-Timolol | 12 | $2,195 | $183 |
| Dorzolamide-Timolol | 63 | $1,011 | $16 |
| Dorzolamide | 28 | $606 | $22 |
| Neomycin-Polymyxin-Dexameth | 31 | $343 | $11 |
| Brimonidine | 24 | $250 | $10 |
Year by year
| 2024 | 536 | 186 | 0% (0) | 51% | $64,505 |
| 2023 | 541 | 166 | 0% (0) | 52% | $66,630 |
| 2022 | 594 | 174 | 0% (0) | 48% | $67,331 |
| 2021 | 683 | 200 | 0% (0) | 55% | $77,233 |
| 2020 | 507 | 163 | 0% (0) | 45% | $55,566 |
| 2019 | 515 | 173 | 0% (0) | 39% | $59,595 |
| 2018 | 68 | 45 | 0% (0) | 41% | $6,953 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 9 drugs
| Restasis | 17 | $14,633 | $861 |
| Lumigan | 18 | $13,898 | $772 |
| Latanoprost | 236 | $6,405 | $27 |
| Timolol Maleate | 72 | $2,681 | $37 |
| Dorzolamide-Timolol | 60 | $2,175 | $36 |
| Dorzolamide-Timolol | 13 | $2,173 | $167 |
| Neomycin-Polymyxin-Dexameth | 25 | $358 | $14 |
| Dorzolamide | 13 | $318 | $24 |
| Brimonidine | 17 | $287 | $17 |
2022: 9 drugs
| Restasis | 16 | $13,370 | $836 |
| Latanoprost | 279 | $8,837 | $32 |
| Combigan | 16 | $7,367 | $460 |
| Lumigan | 13 | $6,822 | $525 |
| Timolol Maleate | 78 | $3,805 | $49 |
| Dorzolamide-Timolol | 50 | $2,616 | $52 |
| Dorzolamide | 13 | $509 | $39 |
| Neomycin-Polymyxin-Dexameth | 21 | $281 | $13 |
| Brimonidine | 17 | $183 | $11 |
2021: 13 drugs
| Restasis | 15 | $16,519 | $1,101 |
| Xiidra | 15 | $13,544 | $903 |
| Latanoprost | 342 | $11,894 | $35 |
| Combigan | 19 | $8,989 | $473 |
| Lumigan | 11 | $6,863 | $624 |
| Alphagan P | 12 | $4,488 | $374 |
| Dorzolamide-Timolol | 61 | $3,210 | $53 |
| Timolol Maleate | 81 | $1,625 | $20 |
| Dorzolamide | 15 | $665 | $44 |
| Brimonidine | 26 | $631 | $24 |
| Acyclovir | 12 | $269 | $22 |
| Neomycin-Polymyxin-Dexameth | 12 | $197 | $16 |
| Erythromycin | 12 | $149 | $12 |
2020: 5 drugs
| Restasis | 15 | $11,354 | $757 |
| Latanoprost | 258 | $8,160 | $32 |
| Dorzolamide-Timolol | 27 | $2,497 | $92 |
| Timolol Maleate | 65 | $1,510 | $23 |
| Dorzolamide | 19 | $956 | $50 |
2019: 9 drugs
| Restasis | 26 | $19,346 | $744 |
| Latanoprost | 201 | $5,419 | $27 |
| Travatan Z | 20 | $4,873 | $244 |
| Timolol Maleate | 74 | $4,288 | $58 |
| Brimonidine | 27 | $3,185 | $118 |
| Dorzolamide-Timolol | 26 | $2,570 | $99 |
| Dorzolamide | 15 | $765 | $51 |
| Prednisolone Acetate | 12 | $682 | $57 |
| Erythromycin | 13 | $155 | $12 |
2018: 2 drugs
| Latanoprost | 27 | $722 | $27 |
| Timolol Maleate | 12 | $599 | $50 |
Money from drug and device companies
$226 in 2025
| 2025 | 4 | 7 | None | $226 |
| 2024 | 4 | 6 | None | $366 |
| 2023 | 2 | 3 | None | $77 |
| 2022 | 3 | 4 | None | $90 |
| 2021 | 1 | 1 | None | $136 |
| 2019 | 3 | 3 | None | $167 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Tarsus Pharmaceuticals | Xdemvy | $143 | 4 payments
|
| Oyster Point Pharma | Tyrvaya | $33 | 1 payment
|
| Johnson & Johnson Vision Care | None | $26 | 1 payment
|
| Dompe US | Oxervate | $24 | 1 payment
|
See all 7 published payments
| Tarsus Pharmaceuticals | Meals · 2025-12-11 | Xdemvy | $8 |
| Tarsus Pharmaceuticals | Meals · 2025-11-19 | Xdemvy | $8 |
| Tarsus Pharmaceuticals | Meals · 2025-10-29 | Xdemvy | $6 |
| Tarsus Pharmaceuticals | Meals · 2025-10-06 | Xdemvy | $121 |
| Johnson & Johnson Vision Care | Meals · 2025-05-09 | None | $26 |
| Oyster Point Pharma | Meals · 2025-03-04 | Tyrvaya | $33 |
| Dompe US | Meals · 2025-01-24 | Oxervate | $24 |
See earlier years (2024, 2023, 2022, 2021, 2019)
2024: $366
| Alcon Vision | Hydrus Microstent | $171 | 2 payments
|
| CooperVision | Myday Contact Lens | $112 | 1 payment
|
| Johnson & Johnson Vision Care | None | $61 | 2 payments
|
| Sight Sciences | Omni Surgical System | $22 | 1 payment
|
2023: $77
| Johnson & Johnson Vision Care | Acuvue | $53 | 2 payments
|
| Biotissue Holdings | Prokera | $24 | 1 payment
|
2022: $90
| Johnson & Johnson Vision Care | Acuvue | $48 | 2 payments
|
| Allergan | Restasis Multidose | $23 | 1 payment
|
| Alcon Vision | Dailies | $19 | 1 payment
|
2021: $136
| Genentech USA | Lucentis | $136 | 1 payment
|
2019: $167
| Allergan | Restasis | $132 | 1 payment
|
| Johnson & Johnson Vision Care | Acuvue | $19 | 1 payment
|
| Alcon Vision | Precision 1 | $17 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 73.7 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1487130886
- Licence
- CA 34001TLG
- Trained
- University of California - School of Optometry, 2018
- Group
- Yura Kim OD Inc · Yk Optometry Inc · Peninsula Eye Physicians Medical Group,Inc.
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 152W00000X (152W00000X)
- Mailing address
- 1190 Scott Blvd, Santa Clara, CA, 95050
- NPI first listed
- 2018-07-18
- NPI last updated
- 2025-10-29
- NPI record certified
- 2025-10-29
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 644 San Antonio Rd, Mountain View, CA, 94040